Novartis
Biopharmaceuticals · Switzerland
Novartis researches, makes and sells prescription medicines in cardiovascular, immunology, neuroscience and cancer, led by Entresto, Cosentyx and Kisqali.
What makes it different
Its biggest medicine lost US patent protection in 2025.
$7.7BEntresto salesFY2025
Newer cancer and multiple sclerosis brands such as Kisqali and Kesimpta now carry the growth.
How big it is
How big is Novartis?
$54.5BNet salesFY2025
75,267EmployeesFY2025
~120CountriesFY2025
How it makes money FY2025
Cancer and immunology medicines lead the sales.
- Oncology31%$16.8B
- Established brands23%$12.5B
- Immunology19%$10.3B
- Cardiovascular, renal and metabolic16%$9.0B
- Neuroscience11%$6.0B
How the business works
Four disease areas, fast launches, bought-in pipeline.
- 1Four core disease areas
- 2Priority brands in ~120 countries
- 3Acquire late-stage medicines
New brands must outgrow generic losses on older drugs such as Entresto, so Novartis keeps buying pipeline.
Who owns it
- BlackRock, Inc.7.3%
- UBS Group AG7.3%
CEO: Vasant (Vas) Narasimhan
Who it competes with
Key moments
- 2-20Ciba-Geigy and Sandoz merge into Novartis
- 2018Buys gene therapy and radioligand companies
- 2018Vas Narasimhan becomes CEO
- 9-04Spins off Alcon eye care
- 2021Sells its Roche stake for USD 20.7 billion
Sources
Every number on this page comes from Novartis's own reports.
Full profile
The rest of the story is in the app.
What Novartis tracks23 metrics
Molecules moved to late-stage development in 2025
Employees
Countries where products are sold
Results, quarter by quarterwith a chart
Revenue
Profit
Margin
Where the money comes from4 regions
United States
Europe
Asia, Africa, Australasia
The full timeline17 moments
2024
2025
2026
Novartis vs Rocheside by side
Revenue
Profit
People
Point your phone at a logo.
See the company behind it.
The full story in 12 chapters · compare any two companies · 335 companies, and any other on request.
Download on the App Store
